Gil Roth12.11.13
Phase I
KaloBios succeeds in early-stage trial . . . read more
Phase II
Seattle Genetics updates Adcetris DLBCL data . . . read more
Phase III
AbbVie regimen wallops HCV . . . read more
Avanir pain drug misses endpoint in MS pain trial . . . read more
Merck advances Alzheimer's drug . . . read more
Filings
Baxter submits OBI-1 BLA . . . read more
Genzyme Gaucher treatment gets priority review . . . read more
Orexigen resubmits Contrave NDA . . . read more
QRxPharma MOXDUO PDUFA date announced . . . read more
KaloBios succeeds in early-stage trial . . . read more
Phase II
Seattle Genetics updates Adcetris DLBCL data . . . read more
Phase III
AbbVie regimen wallops HCV . . . read more
Avanir pain drug misses endpoint in MS pain trial . . . read more
Merck advances Alzheimer's drug . . . read more
Filings
Baxter submits OBI-1 BLA . . . read more
Genzyme Gaucher treatment gets priority review . . . read more
Orexigen resubmits Contrave NDA . . . read more
QRxPharma MOXDUO PDUFA date announced . . . read more